Zenas BioPharma, Inc. (ZBIO) News
Track canonical SquawkNews coverage tagged to ZBIO, Zenas BioPharma, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Zenas BioPharma Price Target Maintained With a $45.00/Share by Wedbush
Ratings actions from Benzinga
NEWS | Sep 30, 2026, 12:36 PM UTC
L
Wedbush reiterates Outperform rating on Zenas BioPharma, $45 price target
Wedbush reiterated their Outperform rating on Zenas BioPharma's stock with a price target of $45.00.The price target implies an upside of 68.2% from the Sep 29 close of $26.76.Key takeaways from the analyst noteDifferent
EQUITY | Sep 30, 2026, 12:26 PM UTC
L
HC Wainwright & Co. reiterates Buy rating on Zenas BioPharma, $44 price target
HC Wainwright & Co. reiterated their Buy rating on Zenas BioPharma's stock with a price target of $44.00.The price target implies an upside of 64.4% from the Sep 29 close of $26.76.Key takeaways from the analyst noteProm
EQUITY | Sep 30, 2026, 10:39 AM UTC
L
ZBIO - Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
ZBIO - Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
NEWS | Sep 22, 2026, 11:05 AM UTC
L
ZBIO - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZBIO - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWS | Sep 18, 2026, 08:15 PM UTC
L
ZBIO: Obexelimab nears FDA decision as pipeline advances and market research signals strong adoption
Significant financial strength supports a robust pipeline, with obexelimab poised for potential FDA approval and launch in IgG4-RD. Market research indicates strong front-line adoption, and multiple late- and early-stage
REGULATION | Sep 14, 2026, 10:18 PM UTC
L
ZBIO: Poised for late-stage launches and data readouts, with strong financials and pipeline momentum
Significant financial strengthening and pipeline expansion position the company for multiple late-stage milestones, including a potential obexelimab launch for IgG4-RD and key data readouts in SLE, MS, and IL-17 programs
NEWS | Sep 14, 2026, 09:15 PM UTC
L
Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Zenas BioPharma, Inc. NASDAQ:ZBIO
REGULATION | Sep 11, 2026, 08:51 PM UTC
L
ZBIO: Obexelimab nears FDA review with strong market potential and pivotal data readouts ahead
Multiple late-stage programs are advancing, with obexelimab under FDA review and key data readouts expected in the coming quarters. Market research suggests strong commercial potential in IgG4-RD, and the company is expa
REGULATION | Sep 09, 2026, 11:15 PM UTC
L
ZBIO: Obexelimab nears FDA review as multiple pipeline assets advance toward key data and regulatory milestones
Multiple late-stage and early pipeline programs are advancing, with obexelimab under FDA review and key data readouts expected for SLE and MS programs. Commercial infrastructure is in place, and filings in Europe are pla
REGULATION | Sep 09, 2026, 09:50 PM UTC
L
Zenas BioPharma to host obexelimab IgG4-RD investor event
Zenas BioPharma says it will host an investor event focused on obexelimab for IgG4-RD.
EQUITY | Sep 08, 2026, 11:07 AM UTC
L
ZBIO - Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
ZBIO - Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
EQUITY | Sep 08, 2026, 11:05 AM UTC
L
Zenas BioPharma to present at upcoming healthcare investor conferences
Zenas BioPharma, Inc. (NASDAQ:ZBIO) said it will present at upcoming healthcare investor conferences.
EQUITY | Sep 04, 2026, 11:07 AM UTC
L
ZBIO - Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
ZBIO - Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
EQUITY | Sep 04, 2026, 11:05 AM UTC
L
13D Filings — Barrons.com
13D Filings — Barrons.com
EQUITY | Aug 28, 2026, 11:47 PM UTC
L
Zenas BioPharma announces inducement grants under Nasdaq Rule 5635(c)(4)
Zenas BioPharma (ZBIO) announces inducement grants under Nasdaq Listing Rule 5635(c)(4), according to TradeXchange Newsdesk.
REGULATION | Aug 18, 2026, 08:15 PM UTC
L
Zenas BioPharma (ZBIO) Reports Q2 2026 Financial Results
Zenas BioPharma reports its second-quarter 2026 financial results and provides a corporate update, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 11:02 AM UTC